Wave Life Sciences Says RNA-Editing Therapy Achieves 'Durable' Serum AAT Protein Production

MT Newswires Live

Sep 03

Wave Life Sciences (WVE) said Wednesday that its experimental RNA-editing therapy WVE-006 achieved "durable" production of serum AAT protein at levels linked to a lower risk of alpha-1 antitrypsin deficiency liver and lung diseases after repeat 200 mg doses in an ongoing phase 1b/2a trial.

The company said data from the 200 mg and 400 mg cohorts support monthly or less frequent dosing, with the 400 mg multidose cohort showing potential to achieve higher serum AAT levels. Data from the 400 mg multidose group are expected in Q1 2026.

Wave Life cited one outlier case showing "marked upregulation" of M-AAT protein, which is protective of lung function, production in a patient experiencing a kidney stone stress response.

The company also said WVE-006 remained well-tolerated with no serious adverse events or discontinuations.

Development rights for WVE-006 will transfer to GSK (GSK) after the current study is completed, Wave Life said.

Shares of the company were down more than 22% in early trading Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564984399"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564984399\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564984399?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564984399","market":"fut","top_or_hot":-1,"title":"Wave Life Sciences Says RNA-Editing Therapy Achieves 'Durable' Serum AAT Protein Production","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences (WVE) said Wednesday that its experimental RNA-editing therapy WVE-006 achieved \"durable\" production of serum AAT protein at levels linked to a lower risk of alpha-1 antitrypsin deficiency liver and lung diseases after repeat 200 mg doses in an ongoing phase 1b/2a trial.</p><p>The company said data from the 200 mg and 400 mg cohorts support monthly or less frequent dosing, with the 400 mg multidose cohort showing potential to achieve higher serum AAT levels. Data from the 400 mg multidose group are expected in Q1 2026.</p><p>Wave Life cited one outlier case showing \"marked upregulation\" of M-AAT protein, which is protective of lung function, production in a patient experiencing a kidney stone stress response.</p><p>The company also said WVE-006 remained well-tolerated with no serious adverse events or discontinuations.</p><p>Development rights for WVE-006 will transfer to GSK (GSK) after the current study is completed, Wave Life said.</p><p>Shares of the company were down more than 22% in early trading Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences Says RNA-Editing Therapy Achieves 'Durable' Serum AAT Protein Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences Says RNA-Editing Therapy Achieves 'Durable' Serum AAT Protein Production\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-03 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences (WVE) said Wednesday that its experimental RNA-editing therapy WVE-006 achieved \"durable\" production of serum AAT protein at levels linked to a lower risk of alpha-1 antitrypsin deficiency liver and lung diseases after repeat 200 mg doses in an ongoing phase 1b/2a trial.</p><p>The company said data from the 200 mg and 400 mg cohorts support monthly or less frequent dosing, with the 400 mg multidose cohort showing potential to achieve higher serum AAT levels. Data from the 400 mg multidose group are expected in Q1 2026.</p><p>Wave Life cited one outlier case showing \"marked upregulation\" of M-AAT protein, which is protective of lung function, production in a patient experiencing a kidney stone stress response.</p><p>The company also said WVE-006 remained well-tolerated with no serious adverse events or discontinuations.</p><p>Development rights for WVE-006 will transfer to GSK (GSK) after the current study is completed, Wave Life said.</p><p>Shares of the company were down more than 22% in early trading Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2564984399","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564984399","pubTimestamp":1756906515,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Wave Life Sciences (WVE) said Wednesday that its experimental RNA-editing therapy WVE-006 achieved \"durable\" production of serum AAT protein at levels linked to a lower risk of alpha-1 antitrypsin def","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4532":"文艺复兴科技持仓","WVE":"Wave Life Sciences Pte. Ltd","BK4588":"碎股","RNA":"Avidity Biosciences, Inc.","BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSK":"葛兰素史克","BK4160":"多样化房地产投资信托v","AAT":"American Assets Trust Inc","BK4585":"ETF&股票定投概念","GSK.UK":"葛兰素史克","BK4505":"高瓴资本持仓"},"translate_title":"Wave Life Sciences表示RNA编辑疗法可实现“持久”血清AAT蛋白生产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAT":1,"GSK":0.9,"GSK.UK":0.6,"RNA":1,"WVE":0.9},"content_text":"Wave Life Sciences (WVE) said Wednesday that its experimental RNA-editing therapy WVE-006 achieved \"durable\" production of serum AAT protein at levels linked to a lower risk of alpha-1 antitrypsin deficiency liver and lung diseases after repeat 200 mg doses in an ongoing phase 1b/2a trial.The company said data from the 200 mg and 400 mg cohorts support monthly or less frequent dosing, with the 400 mg multidose cohort showing potential to achieve higher serum AAT levels. Data from the 400 mg multidose group are expected in Q1 2026.Wave Life cited one outlier case showing \"marked upregulation\" of M-AAT protein, which is protective of lung function, production in a patient experiencing a kidney stone stress response.The company also said WVE-006 remained well-tolerated with no serious adverse events or discontinuations.Development rights for WVE-006 will transfer to GSK (GSK) after the current study is completed, Wave Life said.Shares of the company were down more than 22% in early trading Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}